• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    H

    Hospital Angeles Pedregal

    842论文总数
    8,568引用总数

    论文量&引用量时间轴

    机构学者

    论文(842)

    年份
    起
    –
    止
    排序
    1DLG4-Related Synaptopathy and Coexisting Fabry’s Disease: A Case Report
    Daniel San-Juan, Edmar O Benitez-Alonso, Fabiola M López-Castellanos, Carolayn A Amador-Machuca, Derek Gutiérrez-Maciel, Evelin Z Camacho-Castillo
    2026Annals of Indian Academy of Neurology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Imaging Findings and Diagnostic Challenges in Intrahepatic Cholangiocarcinoma During Pregnancy: a Case Report
    Cynthia N. Gonzalez-Ramirez, Anamari Perochena-Gonzalez, M. Guadalupe Gomez-Perez

    Intrahepatic cholangiocarcinoma (ICC) is exceptionally rare during pregnancy and requires balancing maternal oncologic evaluation with fetal safety. This case report describes non-contrast magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) findings in a woman at 23 weeks’ gestation who presented with abdominal pain and jaundice and was diagnosed with moderately differentiated ICC. Abdominal MRI and MRCP showed an intrahepatic lesion measuring 9 × 9.4 × 8.3 cm, predominantly located in the hepatic hilum. The T2-weighted coronal MRI sequence showed a lobulated, heterogeneously hyperintense intrahepatic tumor. Axial diffusion-weighted imaging (DWI) showed predominantly peripheral diffusion restriction (target-like appearance) with an apparent diffusion coefficient (ADC) of 0.7 × 10-3 mm2/s. The T1-weighted MRI sequence showed a hypointense lesion. The in-phase and out-of-phase sequences revealed central areas of fatty signal. On axial T2-weighted fat-saturation (FS) MRI, the tumor caused subtle liver capsular retraction and obstruction, with dilatation of the left intrahepatic biliary duct to 15.2 mm, corroborated on MRCP. Percutaneous biopsy and histopathologic examination showed moderately differentiated ICC with positive CK7 immunostaining. After biliary drainage, jaundice improved, and the decision was made to continue the pregnancy. This case report highlights the value of non-contrast MRI and MRCP in evaluating intrahepatic lesions during pregnancy, emphasizing their diagnostic utility in this rare clinical context.

    2026Journal of the Mexican Federation of Radiology and Imaging(2026)
    引用
    AI阅读
    加入学术空间
    3The Role of EZH2 Dysregulation in the Pathogenesis of B-cell Lymphomas and Its Implications As a Target Therapy
    Myrna Candelaria

    B-cell lymphomas are a group of heterogeneic diseases. During B-cell development, the germinal center (GC) reaction is a complex process, in which transcripcional programs have an epigenetic regulation. Enhancer of zeste homologue-2 (EZH2) is a histone methyltransferase, which catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3) to control gene transcription critical for cell proliferation, function, differentiation and expansion. It controls the normal biology of germinal B cells. Epigenetic dysregulation is a hallmark of Diffuse large B- cell lymphoma (DLBCL) and follicular lymphoma (FL), with gain of function (GOF) EZH2 mutations. EZH2 is also overexpressed and plays an important role in lymphomagenesis. Follicular lymphoma (FL) pathogenesis includes epigenomic alterations affecting the immunological niche, and their potential consequences on the informational transfer between the microenvironment and tumor B cells. The introduction of novel target therapies and immunotherapeutics modalities in B cell lymphomas has shifted the treatment landscape. Tazemetostat received FDA approval as the first epigenetic therapy for FL. Valemetostat, which inhibits EZH1/2, as well as tazemetostat in combination with other drugs have been subject of recent research. The purpose of this article is to review the role of EZH2 in normal B cell differentiation and in the pathogenesis of B-Cell lymphomas.

    2026Frontiers in oncology(2026)
    引用
    AI阅读
    加入学术空间
    4Condrosarcoma Primario De Mama: Reporte De Caso Y Revisión De La Literatura
    Leopoldo Santiago-Sanabria, Adrián Llano-Tostado, Luz del Carmen Sanabria-Villegas, Paola Iturralde-Rosas Priego, Carlos José Molina-Pérez
    2026Revista de la Facultad de Medicina(2026)
    引用
    AI阅读
    加入学术空间
    5Access Inequities and System Capacity for Lymphoma Care in Latin America: Results from the Grupo De Estudio Latinoamericano De Linfoproliferativos Consortium
    Perla R. Colunga-Pedraza,Alejandra De Las Fuentes-Cepeda,Héctor Alejandro Vaquera Alfaro, Luisa C. Campos-Gonzalez, Alia Guadalupe Ordóñez Ayala, Carlos Emir Córdova Lucio,Laura Korin,Guilherme Fleury Perini,Luis Mario Villela Martínez,David Gómez-Almaguer,Henry Idrobo,Juan Rangel-Patiño,

    PurposeThe integration of diagnostic tools, immunochemotherapy, targeted agents, and cellular therapies such as chimeric antigen receptor T-cell therapy (CAR-T) cells has transformed lymphoma outcomes in high-income countries. However, in Latin America (LATAM), access to these advances remains limited. This study aimed to assess lymphoma care access and institutional capacity in LATAM.MethodsWe conducted a cross-sectional digital survey from July 2025 to August 2025, coordinated by the Grupo de Estudio Latinoamericano de Linfoproliferativos network. The survey captured center-level data covering infrastructure, human resources, diagnostic and therapeutic availability, and clinical research activity. Data were analyzed using descriptive methods.ResultsA total of 73 hematology centers from 16 Latin American countries completed the survey. Most centers were public institutions (53%), with a median number of four hematologists per center (range, 2-10). While basic pathology and flow cytometry were widely available, access to advanced diagnostics was limited. Fifteen centers (21%) lacked immunohistochemistry, and pathology turnaround times exceeded 3 weeks in 56%. Positron emission tomography-computed tomography was available in 41% of centers. Novel therapies such as antibody-drug conjugates, bispecific antibodies, and checkpoint inhibitors were not available or restricted in most centers. Hematopoietic stem-cell transplantation was performed in 41% of centers, whereas commercial CAR-T was available in 5%. Clinical trials were conducted in 34% of centers.ConclusionOur findings highlight striking disparities between guideline-recommended lymphoma care and real-world institutional capacity across LATAM, underscoring the importance of collaborative efforts in building capacity and advocating for equitable access.

    2026JCO Global Oncology(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 842 篇论文

    合作机构(100)

    墨西哥社会保障研究所合作论文 55
    Universidad La Salle México合作论文 32
    Hospital General de México,Secretaria de Salud合作论文 27
    Instituto Nacional de Salud Pública,Secretaria de Salud合作论文 27
    Instituto Nacional de Cancerología,Secretaria de Salud合作论文 23
    墨西哥国立自治大学合作论文 20
    Centro Médico ABC合作论文 14
    Hospital Civil de Guadalajara合作论文 14
    Hospital Español合作论文 13
    Hospital Médica Sur合作论文 13

    机构统计